Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q96IZ6
UPID:
MET2A_HUMAN
Alternative names:
Methyltransferase-like protein 2A
Alternative UPACC:
Q96IZ6; A6NNC4; Q9H9G9; Q9NUI8; Q9P0B5
Background:
The tRNA N(3)-methylcytidine methyltransferase METTL2A, also known as Methyltransferase-like protein 2A, plays a crucial role in post-transcriptional modification of tRNA. It specifically mediates N(3)-methylcytidine modification of residue 32 in the anticodon loop of tRNA(Thr)(UGU) and tRNA(Arg)(CCU), a process essential for the accurate translation of the genetic code into proteins. This modification requires prior N6-threonylcarbamoylation of tRNA by the EKC/KEOPS complex, highlighting a sophisticated level of tRNA modification regulation.
Therapeutic significance:
Understanding the role of tRNA N(3)-methylcytidine methyltransferase METTL2A could open doors to potential therapeutic strategies. Its precise function in tRNA modification suggests a foundational role in protein synthesis, offering a novel angle for targeting diseases through the modulation of genetic translation mechanisms.